Maegim한국어

셀트리온

068270KOSPISector: Pharma & Biotech
₩171,600▼ 0.58%Market cap ₩39.91TAs of Jul 21, 2026 close · updated once daily
A
Grade A66.9 ptsTop 18% of 2,523 stocks
Financial strength
70.4
Growth momentum
82.4
Price attractiveness
51.7

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

70.4
How much debt does it carry relative to equity?
Debt-to-equity ratio
28.7%
✓ Above median · Top 28.3% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
139.3%
✗ Below median · Top 60% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
28.1%
✓ Above median · Top 5.1% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
6.0%
✓ Above median · Top 25% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

82.4
How much did revenue grow in a year?
Revenue growth (YoY)
17.0%
✓ Above median · Top 26.7% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
22.1%
✓ Above median · Top 11.8% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
137.5%
✓ Above median · Top 10.9% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
80.5%
✓ Above median · Top 21.2% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

51.7
Is the price expensive relative to earnings?
P/E (price-to-earnings)
38.8x
✓ Above median · Top 34.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
2.32x
✗ Below median · Top 62.4% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15